# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Louise Chen reiterates Zai Lab (NASDAQ:ZLAB) with a Overweight.
Cantor Fitzgerald analyst Louise Chen reiterates Zai Lab (NASDAQ:ZLAB) with a Overweight.
This is the first compound in Zai's portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai...
Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, ...
The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, inc...